High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study

Anna Jamnitski, Johannes H. Levels, Inge A. van den Oever, Michael T. Nurmohamed

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response. Methods. A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Results. In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months' therapy. There were no significant differences in HDL profiling in EULAR nonresponders. Conclusion. Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition
Original languageEnglish
Pages (from-to)825-830
JournalJournal of Rheumatology
Volume40
Issue number6
DOIs
Publication statusPublished - 2013

Cite this